05 April 2022
20 US Clinical Cancer Centers, 16 Metastatic Breast Cancer Trials now powered by Epic Sciences platform DefineMBC™ assesses breast cancer as it evolves in later stages and new treatments become available
SAN DIEGO, April, 2, 2022Epic Sciences, Inc. has added DefineMBC™, a novel comprehensive blood-based test for characterizing metastatic breast cancer, to its CLIA laboratory menu.
“As one of the many cancer centers eager to begin incorporating DefineMBC™, we are pleased to collaborate with the Epic team on this important launch” commented Lee Schwartzberg MD, FACP, Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, Nevada. “This unique capability to assess receptor status, copy number changes, as well as relevant genomic alterations from one blood draw – and on a single comprehensive report – is groundbreaking, and could absolutely change oncology practice.”
DefineMBC™ includes both cell-based and cell-free analysis from a single blood draw to provide comprehensive profiling of metastatic breast cancer when a tissue biopsy result is not available. The test’s multi-analyte methods have demonstrated impressive sensitivity, specificity, accuracy, and precision in the:
“Developing DefineMBC™ has been an incredible Epic Sciences team effort over the past 3 years says Rick Wenstrup, Chief Medical Officer, Epic Sciences. “We have also benefitted tremendously from the input and ongoing collaboration with multiple leading breast cancer oncologists throughout development. Patients now may have less invasive testing options and oncologists will have more information to guide treatment.” The company is committed to analyzing DefineMBC™ and other breast cancer biomarkers in clinical trials as well as drug development programs to further explore applications with current and future available therapies.
Epic Sciences, Inc. is developing and marketing novel diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancers. The Company’s liquid biopsy platform leverages proven, proprietary cell analysis capabilities as well as cell-free analysis to provide more complete, efficient analysis and clearer insights – Comprehensive Cancer Profiling. Using its full-service CAP/CLIA-accredited laboratory and research support services, Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world to improve patient outcomes.Print
01 July 2022
01 July 2022
30 June 2022
30 June 2022